.png)
Bristol Myers combo follows Roche, AstraZeneca immunotherapy rivals into first-line liver cancer
Bristol Myers Squibb has received the FDA’s green light to compete with Roche's and AstraZeneca's immunotherapy-based treatments in first-line liver cancer.
Bristol Myers Squibb has received the FDA’s green light to compete with Roche's and AstraZeneca's immunotherapy-based treatments in first-line liver cancer.
